Telaprevir combination therapy in HCV/HIV co-infected patients (insight study): sustained virologic response at 12 weeks final analysis

Montes, Marisa; Mark, Nelson; Girard, Pierre Marie; Sasadeusz, Joe; Horban, Andrzej; Grinsztejn, Beatriz; Zakharova, Natalia; Rivero, Antonio; Lathouwers, Erkki; Janssen, Katrien; Mahadevan, Sivi Ouwerkerk; Witek, James.
Artículo en Inglés | ARCA | ID: arc-11203

Documentos relacionados

  1. Measuring Human Immunodeficiency Virus Reservoirs: Do We Need to Choose Between Quantity and Quality?
  2. Impact of fluctuation in frequency of human immunodeficiency virus/simian immunodeficiency virus reactivation during antiretroviral therapy interruption.
  3. Antiretroviral Initiation at ≥800 CD4+ Cells/mm3 Associated With Lower Human Immunodeficiency Virus Reservoir Size.
  4. Changes in health and sleep quality after anti-retroviral treatment modification in Japanese people living with HIV.
  5. HIV, antiretrovirals, and peripheral neuropathy: A moving target.
  6. Reply to Hector et al.
  7. Central Nervous System Safety During Brief Analytic Treatment Interruption of Antiretroviral Therapy Within 4 Human Immunodeficiency Virus Remission Trials: An Observational Study in Acutely Treated People Living With Human Immunodeficiency Virus.
  8. HIV reservoirs as obstacles and opportunities for an HIV cure.
  9. Longitudinal Dynamics of Intact HIV Proviral DNA and Outgrowth Virus Frequencies in a Cohort of Individuals Receiving Antiretroviral Therapy.
  10. Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years.